AB&B BIO-TECH-B (02627) announced the initiation of Phase I clinical trials for its quadrivalent influenza virus subunit vaccine (adjuvanted) and trivalent influenza virus subunit vaccine (adjuvanted). The group had previously obtained approval for clinical trial applications from China's National Medical Products Administration (NMPA) in July 2024 for the quadrivalent vaccine and in October 2024 for the trivalent vaccine.

As immune function naturally declines with age, influenza poses a more severe threat to elderly individuals, particularly those aged 65 and above. This demographic faces higher risks of severe illness and mortality from influenza infections, significantly impacting health and increasing economic burdens.

AB&B BIO-TECH-B's quadrivalent and trivalent influenza subunit vaccines are specifically designed for individuals aged 65 and older. By incorporating an MF59-like adjuvant, these vaccines enhance immune responses and increase antibody titers, providing improved protection for this age group.